Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus

Next Previous
Trial Profile

A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riboflavin (Primary)
  • Indications Keratoconus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Avedro

    • Most Recent Events

    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017.
    • 18 Apr 2016 According to an Avedro media release, based on the data from this and other two trials (see CTP 700245655 and 700238499) the company has received an approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top